NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

多系統萎縮症(MSA)市場:洞察,流行病學以及2030年為止的市場預測

Multiple System Atrophy (MSA) Market Insight, Epidemiology and Market Forecast -2030

出版商 DelveInsight Business Research LLP 商品編碼 980944
出版日期 按訂單生產 內容資訊 英文 160 Pages
商品交期: 2-10個工作天內
價格
多系統萎縮症(MSA)市場:洞察,流行病學以及2030年為止的市場預測 Multiple System Atrophy (MSA) Market Insight, Epidemiology and Market Forecast -2030
出版日期: 按訂單生產內容資訊: 英文 160 Pages
簡介

多系統萎縮症(MSA),以前稱為Shy-Drager症候群,是一種罕見的退化性神經系統疾病,會影響人體的非自主功能,包括血壓,呼吸,膀胱功能和運動控制。多系統萎縮一詞最早是在1969年在醫學文獻中引入的。它涵蓋了以前被認為是單獨疾病的三種疾病的三種表現形式,尤其是Shy-Drager症候群(自主神經功能障礙),紋狀體變性(帕金森氏症),以及偶發性小腦橋小腦萎縮(小腦症狀)。

MSA沒有特定的治療方法。治療旨在通過支持療法(物理療法,職業療法和言語療法)和自主神經症狀的治療來控制疾病的症狀。某些藥物旨在治療某些症狀。有一些用於MSA的藥物,主要可減輕體位性低血壓,帕金森氏病,尿失禁,尿瀦留,便秘和勃起功能障礙。

本報告提供世界主要7個國家(美國,歐洲5個國家(德國,西班牙,義大利,法國,及英國),日本)的多系統萎縮症(MSA)市場相關調查,提供流行病學,市場規模和預測,成長要素及課題,治療方法·各國市場分析,競爭情形,主要企業的產品等資訊。

目錄

第1章 主要洞察

第2章 摘要整理

第3章 市場概要

  • 2017年:整體市場佔有率
  • 2030年:整體市場佔有率

第4章 疾病背景和概要:多系統萎縮症(MSA)

  • 簡介
  • MSA的亞型
    • 帕金森MSA(MSA-P)
    • 腦MSA(MSA-C)
  • 徵兆或症狀
    • MSA共同特徵
  • 細胞神經病理學
  • MSA病因相關機制假設
  • 生物標記
  • 診斷
  • 診斷指南

第5章 患者療程

第6章 流行病學和患者人口

  • 主要調查結果
  • 流行病學調查手法
  • MSA的主要7國總人口
  • MSA的主要7國確診患病率的總合

第7章 各國家MSA的流行病學

  • 美國
    • 前提條件與理論的根據
    • MSA的整體盛行率
    • 確診的MSA的盛行率的總合
    • 各性別確診的MSA的盛行率
    • 各年齡確診的MSA的盛行率
    • MSA的各類型確診患病率
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第8章 目前治療和醫療行為

  • 治療
    • 藥物療法
    • 支持療法

第9章 未滿足需求

第10章 成藥

  • Northera/DOPS (Droxidopa): Chelsea Therapeutics/Sumitomo Dainippon Pharma
    • 藥物概要
    • 法規的里程碑
    • 臨床開發
    • 安全性和有效性
    • 產品簡介

第11章 新藥

  • 競爭情形
  • Verdiperstat(AZD3241; BHV-3241):Biohaven Pharmaceuticals
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • Ampreloxetine (TD-9855): Theravance Biopharma
    • 其他開發活動
  • Rasagiline mesylate (Azilect/TVP-1012): Teva Pharmaceutical Industries
  • Safinamide Methanesulfonate: Zambon SpA
  • NBMI (Irminix, Emeramide): EmeraMed

第12章 市場分析MSA:主要7個國家

  • 主要調查結果
  • 市場調查手法
  • 屬性分析
  • 主要的市場預測的前提條件
  • 主要7個國家的MSA市場規模
  • 主要7個國家的各治療法MSA的市場規模

第13章 市場預測主要7個國家

第14章 新治療方法的可能性

  • 美國的市場規模
    • MSA的整體市場規模
    • 各治療法市場規模
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第15章 市場成長要素

第16章 市場障礙

第17章 SWOT分析

第18章 償付和市場進入

第19章 附錄

  • 參考文獻
  • 報告的調查手法

第20章 DelveInsight的服務內容

第21章 免責聲明

第22章 關於DelveInsight

目錄
Product Code: DIMI0748

DelveInsight's 'Multiple System Atrophy (MSA)-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the MSA, historical and forecasted epidemiology as well as the MSA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The MSA market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM MSA market size from 2017 to 2030. The Report also covers current MSA treatment practices, market drivers, market barriers, unmet medical needs, SWOT analysis to curate the best of the opportunities, and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Multiple System Atrophy (MSA) Disease Understanding and Treatment Algorithm

Multiple System Atrophy (MSA) Overview

Multiple System Atrophy (MSA), formerly known as Shy-Drager Syndrome, is a rare, degenerative neurological disorder affecting the body's involuntary (autonomic) functions, including blood pressure, breathing, bladder function, and motor control. The term multiple system atrophy was first introduced in the medical literature in 1969. It encompasses three presentations of a single disease formerly thought to be separate disorders, specifically Shy-Drager syndrome (which emphasized autonomic dysfunction), striatonigral degeneration (which emphasized parkinsonian symptoms), and sporadic olivopontocerebellar atrophy (which emphasized cerebellar symptoms).

MSA is broken down into two main subtypes based on the predominant symptom: MSA-predominant Parkinsonism (MSA-P) and MSA-predominant cerebellar ataxia (MSA-C). A patient diagnosed with MSA-P may over time appear to have MSA-C and vice versa, so these categorizations are not always set in stone.

Multiple System Atrophy (MSA) Diagnosis

A detailed clinical evaluation, including medical history, physical, and neurological examinations with special attention to gait, coordination, and muscle tone, is the most important step in evaluating a patient with suspected MSA.

Continued in the report…..

Multiple System Atrophy (MSA) Treatment

There is no specific treatment for MSA. Treatment is aimed at controlling the symptoms of the disease with the help of supportive therapies (physiotherapy, occupational therapy, and speech therapy) and treatment of autonomic symptoms. Drugs that are used to treat people with Parkinson's disease, most notably levodopa, may also be prescribed for individuals with MSA. However, the effectiveness of such medications varies significantly among affected individuals. In many cases, individuals do not respond or respond poorly to such therapy. Approximately one-third of affected individuals respond to levodopa therapy. However, in most cases, the effectiveness of this therapy decreases over time. In addition, these drugs must be used with caution because they may lower blood pressure.

Certain medications are designed to treat certain symptoms. There are some medications for MSA, which primarily lessen orthostatic hypotension, parkinsonism, urinary incontinence, urinary retention, constipation, and erectile dysfunction.

Multiple System Atrophy (MSA) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of MSA, Diagnosed Prevalent Patient Population of MSA, Gender-specific Diagnosed Prevalent Population of MSA, Age-specific Diagnosed Prevalent Population of MSA, and Type-specific Diagnosed Prevalent Population of MSA scenario of MSA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Key Findings

  • In 2017, the prevalent cases of MSA in the 7MM was 41,033.
  • The diagnosed patient pool in the 7MM comprised of 22,568 patients in 2017.
  • In the case of the United States, the prevalent population of MSA was 14,496 in 2017.
  • It has been observed that males accounted for more prevalent cases of MSA than females. In 2017, out of the total diagnosed prevalent cases of MSA, 4,784 cases accounted for males and 3,189 for females, in the US.
  • In the epidemiology model of MSA, for age-specific cases, the categorization is done in the following age group, i.e., 30-39 Years, 40-49 Years, 50-59 Years, 60-79 Years, and 80+ Years. In the US, the majority of the cases are observed in the age group, 50-59 Years (51.52%), whereas, in EU-5, and Japan, the majority of the cases are observed in the age group 60-79 Years.
  • MSA is broken down into two main subtypes based on the predominant symptom: MSA-predominant Parkinsonism (MSA-P), and MSA-predominant cerebellar ataxia (MSA-C).
  • In the US and EU-5 countries, MSA-P type is more prevalent as compared to MSA-C type, but in Japan, the trend is the opposite. In Japan, MSA-C type (70%) is more prevalent as compared to MSA-P (30%).
  • In the EU5, the highest prevalent cases were reported to be in Italy followed by Germany, and the United Kingdom whereas the lowest prevalence rates were reported in Spain during the period of 2017-2030.
  • Japan was reported to have 10,360 prevalent cases of MSA in 2017.

Multiple System Atrophy (MSA) Epidemiology

The epidemiology segment also provides the MSA epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Multiple System Atrophy (MSA) Drug Chapters

The drug chapter segment of the MSA report encloses the detailed analysis of MSA current therapies, mid-phase, and late-stage pipeline drugs. It also helps to understand the MSA clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug, and the latest news and press releases.

Multiple System Atrophy (MSA) Marketed Drugs

Northera/DOPS (Droxidopa): Chelsea Therapeutics/Sumitomo Dainippon Pharma

Northera (droxidopa) is an oral medicine used to treat sensations of dizziness, light-headedness, and a feeling of being on the verge of passing out or fainting - all symptoms that may result from a neurological disorder like Parkinson's disease. Northera is in a class of medications called alpha and beta-adrenergic agonists, which work by increasing norepinephrine levels. Norepinephrine is a natural circulating chemical that helps to regulate blood pressure. Northera is directly metabolized to norepinephrine by a naturally occurring enzyme called dopa-dexarboxylase. Droxidopa has been marketed in Japan since 1989. In 2014, it was approved in the US.

Products detail in the report…

Multiple System Atrophy (MSA) Emerging Drugs

Verdiperstat (AZD3241; BHV-3241): Biohaven Pharmaceuticals

Verdiperstat is a first-in-class, oral, potent, selective, brain-penetrant, and irreversible myeloperoxidase (MPO) enzyme inhibitor. Since MPO is a key driver of oxidative and inflammatory processes and is significantly increased in a range of brain disorders, it is thought that inhibiting MPO activity may be a promising therapeutic strategy for neuroinflammatory and neurodegenerative conditions, including MSA.

Verdiperstat was progressed through Phase II clinical trials by AstraZeneca. Seven clinical studies were completed by AstraZeneca, including four Phase I studies in healthy subjects, two Phase IIa studies in subjects with Parkinson's disease, and one phase IIb study in subjects with MSA. These Phase II clinical studies provide evidence that verdiperstat achieves peripheral target engagement (i.e., reduces MPO specific activity in plasma) and central target engagement in the brain and offer proof of its mechanism of action (i.e., reduce microglial activation and neuroinflammation).

A Phase III clinical trial to evaluate the efficacy of verdiperstat in MSA is currently ongoing. The trial's topline results are expected in the fourth quarter of 2021. The China IND approval to join the Phase III clinical trial of verdiperstat for the treatment of MSA was obtained in the fourth quarter of 2019.

In addition, Phase II/III trial to evaluate the efficacy of verdiperstat in amyotrophic lateral sclerosis (ALS) is currently ongoing as part of the HEALEY ALS platform trial.

Products detail in the report…

Ampreloxetine (TD-9855): Theravance Biopharma

Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor (NRI) in development for the treatment of patients with symptomatic orthostatic hypotension (nOH). It has a high affinity for binding to norepinephrine transporters. By blocking the action of these transporters, ampreloxetine causes an increase in extracellular concentrations of norepinephrine.

Ampreloxetine showed positive 4-week results from a Phase II study in patients with nOH, including durable improvements in patients' disease symptom severity after 4 weeks of treatment with ampreloxetine, as measured by orthostatic hypotension symptom assessment question #1 ("OHSA #1"). OHSA #1 is a measure of dizziness, lightheadedness, or the sensation of being about to blackout. Ampreloxetine is currently being evaluated in the registrational Phase III program in patients with symptomatic nOH, and the company is expecting 4-week efficacy data in 2021. The ongoing Phase 3 registrational program includes two studies, one designed to assess treatment benefit over 4 weeks and the other to assess the response's durability.

Products detail in the report…

List to be continued in the report…

Multiple System Atrophy (MSA) Market Outlook

The current treatment only offers symptomatic relief. The symptomatic treatment options include medications for orthostatic hypotension, parkinsonism, urinary incontinence, urinary retention, constipation, and erectile dysfunction. No disease-modifying treatment option is currently available in the market.

The fainting and lightheadedness from orthostatic hypotension may be treated with simple interventions such as wearing compression stockings, adding extra salt and/or water to the diet, and avoiding heavy meals. The drugs fludrocortisone and midodrine sometimes are prescribed. Northera/DOPS (droxidopa) is approved in the US and Japan to treat neurogenic orthostatic hypotension seen in MSA. ProAmatine/Gutron (midodrine hydrochloride) is also approved in the US and some EU countries. ProAmatine, developed by Shire Plc - now acquired by Takeda, is discontinued in the US; however, generic versions are available in the US market.

Bladder control problems are treated according to the nature of the problem. Anticholinergic drugs, such as oxybutynin or tolterodine, may help reduce the sudden urge to urinate. Fixed abnormal muscle postures (dystonia) may be controlled with injections of botulinum toxin, and sleep problems such as REM sleep behavior disorder can be treated with medicines including clonazepam, melatonin, or some antidepressants. Some individuals with MSA may have significant difficulties with swallowing and may need a feeding tube or nutritional support. Also, speech therapy may help identify strategies to address swallowing difficulties.

Physical therapy helps maintain mobility, reduce contractures (chronic shortening of muscles or tendons around joints, preventing the joints from moving freely), and decrease muscle spasms and abnormal posture. Individuals may eventually need assistive devices such as walkers and wheelchairs. Occupational therapists help with home safety and teach new ways to address daily living activities such as dressing and eating.

Low-dose clonazepam at bedtime can be considered a treatment for a severe rapid-eye-movement sleep behavior disorder, but it may aggravate nocturnal stridor or sleep apnea. Preliminary evidence suggests that melatonin may be an alternative treatment in this situation. Cognitive impairment in patients with MSA does not usually require treatment, but pharmacologic intervention may be needed for those with severe depression, anxiety, or emotional incontinence.

Acetylcholinesterase inhibitors, such as pyridostigmine, indirectly activate muscarinic acetylcholine receptors in autonomic pathways, thus enhancing the force of bladder contractions and reducing PVR volumes. Treatment with acetylcholinesterase inhibitors can also improve postural hypotension symptoms, presumably by enhancing nicotinic acetylcholine receptor activation in the sympathetic ganglia.

The pipeline of MSA possesses potential drugs as monotherapies as well as combination therapies. Overall, the MSA therapeutics market is further expected to grow in the forecast period (2020-2030).

Key Findings

  • The market size of MSA in the 7MM was USD 81.41 million in 2017.
  • In 2017, the market size of MSA in the US was USD 39.63 million.
  • Among the EU-5 countries, Italy has the highest market size of USD 5.84 million followed by Germany and the UK. The lowest market size was estimated in Spain with USD 2.89 million in 2017.
  • Of the emerging therapies, Verdiperstat (AZD 3241; BHV-3241): Biohaven Pharmaceuticals and Ampreloxetine (TD-9855): Theravance Biopharma are expected to enter the market in the 7MM, during the forecast period [2020-2030]. Among these therapies, Verdiperstat is a disease-modifying therapy so it is expected to generate a major market share. This drug is expected to launch in the year 2022 in the US and 2023 in the EU-5 and Japan market.
  • Another therapy Ampreloxetine (TD-9855) is expected to enter in 2023 in the US and 2024 in the EU-5 and Japan market. This drug will compete with an already approved drug (Droxidopa) for neurogenic orthostatic hypotension, due to its high safety profile and once-daily doses, it is anticipated to capture a decent market share in the upcoming years.
  • The market size of MSA in Japan was USD 19.14 million in 2017.

The United States Market Outlook

This section provides the total MSA market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total MSA market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total MSA market size and market size by therapies in Japan are provided.

Multiple System Atrophy (MSA) Drugs Uptake

This section focuses on the rate of uptake of the drugs expected to get launched in the market during the study period 2017-2030. The analysis covers MSA market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Multiple System Atrophy (MSA) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for MSA emerging therapies.

Reimbursement Scenario in Multiple System Atrophy (MSA)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the MSA market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of MSA, explaining its signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the MSA epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for MSA is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the MSA market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM MSA market.

Report Highlights:

  • The increasing prevalence of the disease along with promising emerging pipeline therapies will positively drive the MSA market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence MSA R&D.
  • Major players are involved in developing therapies for MSA. The launch of emerging therapies will significantly impact the MSA market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Multiple System Atrophy (MSA) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • MSA Pipeline Analysis
  • MSA Market Size and Trends
  • Market Opportunities
  • Impact of Upcoming Therapies

Multiple System Atrophy (MSA) Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • MSA Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Multiple System Atrophy (MSA) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT Analysis
  • Market Access and Reimbursement

Key Questions:

Market Insights:

  • What was the MSA market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the MSA total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest MSA market size during the forecast period (2020-2030)?
  • At what CAGR, the MSA market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the MSA market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the MSA market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of MSA?
  • What is the historical MSA patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of MSA at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to MSA?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of MSA during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of MSA along with the approved therapy?
  • What are the MSA emerging drugs and their MOA, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of MSA?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of MSA?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the MSA therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for MSA and their status?
  • What are the key designations that have been granted for the emerging therapies for MSA?
  • What are the 7MM historical and forecasted market of MSA?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the MSA.
  • To understand the future market competition in the MSA market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for MSA in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the MSA market.
  • To understand the future market competition in the MSA market.

Table of Contents

1. Key Insights

2. Executive Summary of Multiple System Atrophy (MSA)

3. Multiple System Atrophy (MSA) Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of Multiple System Atrophy in 2017
  • 3.2. Market Share (%) Distribution of Multiple System Atrophy in 2030

4. Disease Background and Overview: Multiple System Atrophy (MSA)

  • 4.1. Introduction
  • 4.2. Subtypes of MSA
    • 4.2.1. Parkinsonian MSA (MSA-P)
    • 4.2.2. Cerebral MSA (MSA-C)
  • 4.3. Signs or symptoms
    • 4.3.1. Common and distinguishing features of MSA
  • 4.4. Cellular Neuropathology
  • 4.5. Working Hypothesis for the Pathogenesis of MSA
  • 4.6. Biomarkers
  • 4.7. Diagnosis
  • 4.8. Diagnosis Guidelines

5. Patient Journey

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. Epidemiology Methodology
  • 6.3. 7MM Total Prevalent Population of MSA
  • 6.4. 7MM Total Diagnosed Prevalence of MSA

7. Country Wise-Epidemiology of MSA

  • 7.1. United States
    • 7.1.1. Assumptions and Rationale
    • 7.1.2. Total Prevalent Cases of MSA in the United States
    • 7.1.3. Total Diagnosed Prevalent Cases of MSA in the United States
    • 7.1.4. Gender-specific Diagnosed Prevalent Cases of MSA in the United States
    • 7.1.5. Age-specific Diagnosed Prevalent Cases of MSA in the United States
    • 7.1.6. Type-specific Diagnosed Prevalent Cases of MSA in the United States
  • 7.2. EU-5 Countries
    • 7.2.1. Assumptions and Rationale
    • 7.2.2. Germany
      • 7.2.2.1. Total Prevalent Cases of MSA in Germany
      • 7.2.2.2. Total Diagnosed Prevalent Cases of MSA in Germany
      • 7.2.2.3. Gender-specific Diagnosed Prevalent Cases of MSA in Germany
      • 7.2.2.4. Age-specific Diagnosed Prevalent Cases of MSA in Germany
      • 7.2.2.5. Type-specific Diagnosed Prevalent Cases of MSA in Germany
    • 7.2.3. France
      • 7.2.3.1. Total Prevalent Cases of MSA in France
      • 7.2.3.2. Total Diagnosed Prevalent Cases of MSA in France
      • 7.2.3.3. Gender-specific Diagnosed Prevalent Cases of MSA in France
      • 7.2.3.4. Age-specific Diagnosed Prevalent Cases of MSA in France
      • 7.2.3.5. Type-specific Diagnosed Prevalent Cases of MSA in France
    • 7.2.4. Italy
      • 7.2.4.1. Total Prevalent Cases of MSA in Italy
      • 7.2.4.2. Total Diagnosed Prevalent Cases of MSA in Italy
      • 7.2.4.3. Gender-specific Diagnosed Prevalent Cases of MSA in Italy
      • 7.2.4.4. Age-specific Diagnosed Prevalent Cases of MSA in Italy
      • 7.2.4.5. Type-specific Diagnosed Prevalent Cases of MSA in Italy
    • 7.2.5. Spain
      • 7.2.5.1. Total Prevalent Cases of MSA in Spain
      • 7.2.5.2. Total Diagnosed Prevalent Cases of MSA in Spain
      • 7.2.5.3. Gender-specific Diagnosed Prevalent Cases of MSA in Spain
      • 7.2.5.4. Age-specific Diagnosed Prevalent Cases of MSA in Spain
      • 7.2.5.5. Type-specific Diagnosed Prevalent Cases of MSA in Spain
    • 7.2.6. United Kingdom
      • 7.2.6.1. Total Prevalent Cases of MSA in the UK
      • 7.2.6.2. Total Diagnosed Prevalent Cases of MSA in the UK
      • 7.2.6.3. Gender-specific Diagnosed Prevalent Cases of MSA in the UK
      • 7.2.6.4. Age-specific Diagnosed Prevalent Cases of MSA in the UK
      • 7.2.6.5. Type-specific Diagnosed Prevalent Cases of MSA in the UK
  • 7.3. Japan
    • 7.3.1. Assumptions and Rationale
    • 7.3.2. Total Prevalent Cases of MSA in Japan
    • 7.3.3. Total Diagnosed Prevalent Cases of MSA in Japan
    • 7.3.4. Gender-specific Diagnosed Prevalent Cases of MSA in Japan
    • 7.3.5. Age-specific Diagnosed Prevalent Cases of MSA in Japan
    • 7.3.6. Type-specific Diagnosed Prevalent Cases of MSA in Japan

8. Current Treatment and Medical Practices

  • 8.1. Treatment
    • 8.1.1. Drug Therapies
      • 8.1.1.1. Levodopa
      • 8.1.1.2. Dopamine Agonists
      • 8.1.1.3. Amantadine
      • 8.1.1.4. Antidepressants
    • 8.1.2. Supportive Therapies

9. Unmet Needs

10. Marketed Drugs

  • 10.1. Northera/DOPS (Droxidopa): Chelsea Therapeutics/Sumitomo Dainippon Pharma
    • 10.1.1. Drug Description
    • 10.1.2. Regulatory Milestones
    • 10.1.3. Clinical Development
      • 10.1.3.1. Clinical Trials Information
    • 10.1.4. Safety and Efficacy
    • 10.1.5. Product Profile

11. Emerging Drugs

  • 11.1. Key Cross Competition
  • 11.2. Verdiperstat (AZD3241; BHV-3241): Biohaven Pharmaceuticals
    • 11.2.1. Product Description
    • 11.2.2. Other Developmental Activities
    • 11.2.3. Clinical Development
      • 11.2.3.1. Clinical Trials Information
    • 11.2.4. Safety and Efficacy
    • 11.2.5. Product Profile
  • 11.3. Ampreloxetine (TD-9855): Theravance Biopharma
    • 11.3.1. Product Description
    • 11.3.2. Other developmental activities
    • 11.3.3. Clinical Development
      • 11.3.3.1. Clinical Trials Information
    • 11.3.4. Safety and Efficacy
    • 11.3.5. Product Profile
  • 11.4. Rasagiline mesylate (Azilect/TVP-1012): Teva Pharmaceutical Industries
    • 11.4.1. Product Description
    • 11.4.2. Other Developmental Activities
    • 11.4.3. Clinical Development
      • 11.4.3.1. Clinical Trials Information
    • 11.4.4. Safety and Efficacy
    • 11.4.5. Product Profile
  • 11.5. Safinamide Methanesulfonate: Zambon SpA
    • 11.5.1. Product Description
    • 11.5.2. Other Developmental Activities
    • 11.5.3. Clinical Development
      • 11.5.3.1. Clinical Trials Information
    • 11.5.4. Product Profile
  • 11.6. NBMI (Irminix, Emeramide): EmeraMed
    • 11.6.1. Product Description
    • 11.6.2. Other Developmental Activities
    • 11.6.3. Clinical Development
      • 11.6.3.1. Clinical Trials Information
    • 11.6.4. Safety and Efficacy
    • 11.6.5. Product Profile

12. MSA: 7MM Market Analysis

  • 12.1. Key Findings
  • 12.2. Market Methodology
  • 12.3. Attribute Analysis
  • 12.4. Key Market Forecast Assumptions
  • 12.5. Market Size of MSA in the 7MM
  • 12.6. Market Size of MSA by Therapies in the 7MM

13. 7MM Market Outlook

14. Potential of Emerging Therapies

  • 14.1. United States Market Size
    • 14.1.1. Total Market Size of MSA
    • 14.1.2. Market Size by Therapies
  • 14.2. EU-5 Countries
    • 14.2.1. Germany
      • 14.2.1.1. Total Market Size of MSA in Germany
      • 14.2.1.2. Market Size by Therapies
    • 14.2.2. France
      • 14.2.2.1. Total Market Size of MSA
      • 14.2.2.2. Market Size by Therapies
    • 14.2.3. Italy
      • 14.2.3.1. Total Market Size of MSA
      • 14.2.3.2. Market Size by Therapies
    • 14.2.4. Spain
      • 14.2.4.1. Total Market Size of MSA in Spain
      • 14.2.4.2. Market Size by Therapies
    • 14.2.5. United Kingdom
      • 14.2.5.1. Total Market Size of MSA
      • 14.2.5.2. Market Size by Therapies
  • 14.3. Japan
    • 14.3.1. Total Market Size of MSA
    • 14.3.2. Market Size by Therapies

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Reimbursement and Market Access

19. Appendix

  • 19.1. Bibliography
  • 19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Tables

  • Table 1 Summary of Multiple System Atrophy (MSA), Market, Epidemiology, and Key Events (2017-2030)
  • Table 2 Criteria for possible MSA
  • Table 3 Additional features of possible MSA
  • Table 4 Criteria for the diagnosis of probable MSA
  • Table 5 Features supporting (red flags) and not supporting a diagnosis of MSA
  • Table 6 Total Prevalence of MSA in the 7MM (2017-2030)
  • Table 7 Total Diagnosed Prevalence of MSA in the 7MM (2017-2030)
  • Table 8 Total Prevalent Cases of MSA in the United States (2017-2030)
  • Table 9 Total Diagnosed Prevalent Cases of MSA in the United States (2017-2030)
  • Table 10 Gender-specific Diagnosed Prevalent Cases of MSA in the United States (2017-2030)
  • Table 11 Age-specific Diagnosed Prevalent Cases of MSA in the United States (2017-2030)
  • Table 12 Type-specific Diagnosed Prevalent Cases of MSA in the United States (2017-2030)
  • Table 13 Total Prevalent Cases of MSA in Germany (2017-2030)
  • Table 14 Total Diagnosed Prevalent Cases of MSA in Germany (2017-2030)
  • Table 15 Gender-specific Diagnosed Prevalent Cases of MSA in Germany (2017-2030)
  • Table 16 Age-specific Diagnosed Prevalent Cases of MSA in Germany (2017-2030)
  • Table 17 Type-specific Diagnosed Prevalent Cases of MSA in Germany (2017-2030)
  • Table 18 Total Prevalent Cases of MSA in France (2017-2030)
  • Table 19 Total Diagnosed Prevalent Cases of MSA in France (2017-2030)
  • Table 20 Gender-specific Diagnosed Prevalent Cases of MSA in France (2017-2030)
  • Table 21 Age-specific Diagnosed Prevalent Cases of MSA in France (2017-2030)
  • Table 22 Type-specific Diagnosed Prevalent Cases of MSA in France (2017-2030)
  • Table 23 Total Prevalent Cases of MSA in Italy (2017-2030)
  • Table 24 Total Diagnosed Prevalent Cases of MSA in Italy (2017-2030)
  • Table 25 Gender-specific Diagnosed Prevalent Cases of MSA in Italy (2017-2030)
  • Table 26 Age-specific Diagnosed Prevalent Cases of MSA in Italy (2017-2030)
  • Table 27 Type-specific Diagnosed Prevalent Cases of MSA in Italy (2017-2030)
  • Table 28 Total Prevalent Cases of MSA in Spain (2017-2030)
  • Table 29 Total Diagnosed Prevalent Cases of MSA in Spain (2017-2030)
  • Table 30 Gender-specific Diagnosed Prevalent Cases of MSA in Spain (2017-2030)
  • Table 31 Age-specific Diagnosed Prevalent Cases of MSA in Spain (2017-2030)
  • Table 32 Type-specific Diagnosed Prevalent Cases of MSA in Spain (2017-2030)
  • Table 33 Total Prevalent Cases of MSA in the UK (2017-2030)
  • Table 34 Total Diagnosed Prevalent Cases of MSA in the UK (2017-2030)
  • Table 35 Gender-specific Diagnosed Prevalent Cases of MSA in the UK (2017-2030)
  • Table 36 Age-specific Diagnosed Prevalent Cases of MSA in the UK (2017-2030)
  • Table 37 Type-specific Diagnosed Prevalent Cases of MSA in the UK (2017-2030)
  • Table 38 Total Prevalent Cases of MSA in Japan (2017-2030)
  • Table 39 Total Diagnosed Prevalent Cases of MSA in Japan (2017-2030)
  • Table 40 Gender-specific Diagnosed Prevalent Cases of MSA in Japan (2017-2030)
  • Table 41 Age-specific Diagnosed Prevalent Cases of MSA in Japan (2017-2030)
  • Table 42 Type-specific Diagnosed Prevalent Cases of MSA in Japan (2017-2030)
  • Table 43 Symptomatic treatments for MSA patients
  • Table 44 Treatment recommendations for MSA by American Autonomic Society and the American Academy of Neurology
  • Table 45 Northera/DOPS (Droxidopa), Clinical Trial Description, 2020
  • Table 46 Comparison of emerging drugs under development
  • Table 47 Verdiperstat, Clinical Trial Description, 2020
  • Table 48 Ampreloxetine (TD-9855), Clinical Trial Description, 2020
  • Table 49 Rasagiline mesylate (Azilect/TVP-1012), Clinical Trial Description, 2020
  • Table 50 Safinamide Methanesulfonate, Clinical Trial Description, 2020
  • Table 51 NBMI, Clinical Trial Description, 2020
  • Table 52 Key Market Forecast Assumptions for Verdiperstat
  • Table 53 Key Market Forecast Assumptions for Ampreloxetine
  • Table 54 Market Size of MSA in the 7MM in USD Million (2017-2030)
  • Table 55 Market Size of MSA by therapies in the 7MM, in USD Million (2017-2030)
  • Table 56 United States Market Size of MSA, USD Million (2017-2030)
  • Table 57 Market Size of MSA by therapies in the United States, in USD Million (2017-2030)
  • Table 58 Market Size of MSA in Germany, in USD Million (2017-2030)
  • Table 59 Market Size of MSA by therapies in Germany, in USD Million (2017-2030)
  • Table 60 Market Size of MSA in France, in USD Million (2017-2030)
  • Table 61 Market Size of MSA by therapies in France, in USD Million (2017-2030)
  • Table 62 Market Size of MSA in Italy, in USD Million (2017-2030)
  • Table 63 Market Size of MSA by therapies in Italy, in USD Million (2017-2030)
  • Table 64 Market Size of MSA in Spain, in USD Million (2017-2030)
  • Table 65 Market Size of MSA by therapies in Spain, in USD Million (2017-2030)
  • Table 66 Market Size of MSA in the UK, in USD Million (2017-2030)
  • Table 67 Market Size of MSA by therapies in the UK, in USD Million (2017-2030)
  • Table 68 Market Size of MSA in Japan, in USD Million (2017-2030)
  • Table 69 Market Size of MSA by therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1 Causes of Multiple System Atrophy (MSA)
  • Figure 2 Subtype of MSA
  • Figure 3 Locating the Cerebellum and Basal Ganglia
  • Figure 4 Symptoms of MSA
  • Figure 5 Possible pathological α-Syn-spreading and accumulation mechanism leading to neurodegeneration
  • Figure 6 Current and future diagnostic biomarkers of MSA
  • Figure 7 Diagnosis of MSA
  • Figure 8 Diagnostic scheme for MSA according to the current consensus diagnostic criteria
  • Figure 9 Limitations of clinical diagnosis based on clinical signs and symptoms
  • Figure 10 Related Disorders
  • Figure 11 Patient Journey of MSA
  • Figure 12 Total Prevalence of MSA in the 7MM (2017-2030)
  • Figure 13 Total Diagnosed Prevalence of MSA in the 7MM (2017-2030)
  • Figure 14 Total Prevalent Cases of MSA in the United States (2017-2030)
  • Figure 15 Total Diagnosed Prevalent Cases of MSA in the United States (2017-2030)
  • Figure 16 Gender-specific Diagnosed Prevalent Cases of MSA in the United States (2017-2030)
  • Figure 17 Age-specific Diagnosed Prevalent Cases of MSA in the United States (2017-2030)
  • Figure 18 Type-specific Diagnosed Prevalent Cases of MSA in the United States (2017-2030)
  • Figure 19 Total Prevalent Cases of MSA in Germany (2017-2030)
  • Figure 20 Total Diagnosed Prevalent Cases of MSA in Germany (2017-2030)
  • Figure 21 Gender-specific Diagnosed Prevalent Cases of MSA in Germany (2017-2030)
  • Figure 22 Age-specific Diagnosed Prevalent Cases of MSA in Germany (2017-2030)
  • Figure 23 Type-specific Diagnosed Prevalent Cases of MSA in Germany (2017-2030)
  • Figure 24 Total Prevalent Cases of MSA in France (2017-2030)
  • Figure 25 Total Diagnosed Prevalent Cases of MSA in France (2017-2030)
  • Figure 26 Gender-specific Diagnosed Prevalent Cases of MSA in France (2017-2030)
  • Figure 27 Age-specific Diagnosed Prevalent Cases of MSA in France (2017-2030)
  • Figure 28 Type-specific Diagnosed Prevalent Cases of MSA in France (2017-2030)
  • Figure 29 Total Prevalent Cases of MSA in Italy (2017-2030)
  • Figure 30 Total Diagnosed Prevalent Cases of MSA in Italy (2017-2030)
  • Figure 31 Gender-specific Diagnosed Prevalent Cases of MSA in Italy (2017-2030)
  • Figure 32 Age-specific Diagnosed Prevalent Cases of MSA in Italy (2017-2030)
  • Figure 33 Type-specific Diagnosed Prevalent Cases of MSA in Italy (2017-2030)
  • Figure 34 Total Prevalent Cases of MSA in Spain (2017-2030)
  • Figure 35 Total Diagnosed Prevalent Cases of MSA in Spain (2017-2030)
  • Figure 36 Gender-specific Diagnosed Prevalent Cases of MSA in Spain (2017-2030)
  • Figure 37 Age-specific Diagnosed Prevalent Cases of MSA in Spain (2017-2030)
  • Figure 38 Type-specific Diagnosed Prevalent Cases of MSA in Spain (2017-2030)
  • Figure 39 Total Prevalent Cases of MSA in the UK (2017-2030)
  • Figure 40 Total Diagnosed Prevalent Cases of MSA in the UK (2017-2030)
  • Figure 41 Gender-specific Diagnosed Prevalent Cases of MSA in the UK (2017-2030)
  • Figure 42 Age-specific Diagnosed Prevalent Cases of MSA in the UK (2017-2030)
  • Figure 43 Type-specific Diagnosed Prevalent Cases of MSA in the UK (2017-2030)
  • Figure 44 Total Prevalent Cases of MSA in japan (2017-2030)
  • Figure 45 Total Diagnosed Prevalent Cases of MSA in Japan (2017-2030)
  • Figure 46 Gender-specific Diagnosed Prevalent Cases of MSA in Japan (2017-2030)
  • Figure 47 Age-specific Diagnosed Prevalent Cases of MSA in Japan (2017-2030)
  • Figure 48 Type-specific Diagnosed Prevalent Cases of MSA in Japan (2017-2030)
  • Figure 49 Treatment of MSA
  • Figure 50 Unmet Needs
  • Figure 51 Market Size of MSA in the 7MM in USD Million (2017-2030)
  • Figure 52 Market Size of MSA by Therapies in the 7MM, in USD Million (2017-2030)
  • Figure 53 Market Size of MSA in the United States, USD Millions (2017-2030)
  • Figure 54 Market Size of MSA by Therapies in the United States, USD Millions (2017-2030)
  • Figure 55 Market Size of MSA in Germany, USD Million (2017-2030)
  • Figure 56 Market Size of MSA by Therapies in Germany, in USD Million (2017-2030)
  • Figure 57 Market Size of MSA in France, USD Million (2017-2030)
  • Figure 58 Market Size of MSA by Therapies in France, in USD Million (2017-2030)
  • Figure 59 Market Size of MSA in Italy, USD Million (2017-2030)
  • Figure 60 Market Size of MSA by Therapies in Italy, in USD Million (2017-2030)
  • Figure 61 Market Size of MSA in Spain, USD Million(2017-2030)
  • Figure 62 Market Size of MSA by Therapies in Spain, in USD Million (2017-2030)
  • Figure 63 Market Size of MSA in the UK, USD Million (2017-2030)
  • Figure 64 Market Size of MSA by Therapies in the UK, in USD Million (2017-2030)
  • Figure 65 Market Size of MSA in Japan, USD Million (2017-2030)
  • Figure 66 Market Size of MSA by Therapies in Japan, in USD Million (2017-2030)
  • Figure 67 Market Drivers
  • Figure 68 Market Barriers
  • Figure 69 SWOT Analysis of MSA